Sanguisorba officinalis extract, ziyuglycoside I, and II exhibit antiviral effects against hepatitis B virus
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q4Scopus Q2
- 저널
- EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE20 · pp.165 · 2018
- 피인용
- Web of Science 11Scopus 10
- FWCI (Scopus)
- 0.48
- JCR IF
- JCR 2017 0.698
- ISSN
- 1876-3820
저자
- Jang, Eungyeong제1저자Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, South Korea
- Kim, SoyoungDepartment of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul, South Korea
- Lee, Na-RaeDepartment of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul, South Korea
- Kim, HayeonDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea
- Chae, SooinDepartment of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, South Korea
- 한창우DepartM, ment of Internal, edicine, Korean Medicine Hospital, Pusan National University, Yangsan, South Korea
- Kim, YoungchulDepartment of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, South Korea
- Lee, Kyung-TaeDepartment of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, South Korea
- Kim, Bum-JoonDepartment of Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, School of Medicine, Seoul National University, Seoul, South Korea
- Inn, Kyung-Soo교신저자Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul, South Korea
- Lee, Jang-HoonDepartment of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, South Korea
초록
Introduction: Sanguisorba officinalis (SO) has been commonly used to relieve dermatitis, burns, intestinal infections, hematemesis, and melena for a long time in China, Korea, and Japan. The aim of this study was to investigate the antiviral effects of 30% ethanol extract of SO (SOE) and its major compounds (ziyuglycoside I and II) against HBV in HepG2.2.15 cells and HepG2 cells transfected with HBV genotype C. Methods: The antiviral activities of SOE were evaluated by ELISA and quantitative RT-PCR assay in in vitro models. In addition, its effect on HBsAg level was compared to entecavir (ETV), and its co-treatment with ETV was performed to observe combination efficacy. After HPLC analysis of ziyuglycoside I and II, the effects of those compounds on HBsAg levels were measured. Results: SOE, ziyuglycoside I, and II significantly reduced HBsAg excretion and the pgRNA levels in HepG2.2.15 cells. In particular, SOE treatment of 100 mu g/ml showed an inhibitory effect on HBsAg excretion similar to the levels found with ETV treatment of the same concentration. Additional use of 125 mu g/ml of SOE in combination with 80 mu M of ETV inhibited HBsAg production up to the level that is diminished by 320 mu M ETV treatment in HepG2.2.15 cells. Among SOE, ziyuglycoside I, II, and ETV, ziyuglycoside II had the lowest inhibitory concentration of 50% against genotype D, and it was more potent against HBV genotype C than D in down-regulating HBsAg secretion. Conclusion: Taken together, SOE noticeably inhibited replication and antigen secretion of HBV, which was at least in part attributed to ziyuglycoside II, thus presenting the possibility of developing therapeutic candidates for the treatment of HBV-related diseases.
키워드
Sanguisorba officinalisZiyuglycoside IZiyuglycoside IIHepatitis B virusGenotype CHepG2.2.15CELL-CYCLE ARRESTTRITERPENOID SAPONINSAPOPTOSISGENOTYPESPATHWAYROOTRESISTANCEINDUCTIONENTRY
식별자
- Scopus EID
- 2-s2.0-85047630607
- WoS UID
- 000436616200018



로그인
연구물 목록으로